Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Gene Expression in Obesity and Insulin Resistance (Genobin)
This study has been completed.
Sponsors and Collaborators: University of Kuopio
Wageningen University
Information provided by: University of Kuopio
ClinicalTrials.gov Identifier: NCT00621205
  Purpose

Lifestyle and genetic factors interact in the development of obesity and the metabolic syndrome. The molecular mechanisms underlying the beneficial dietary modifications are, however, unclear. We aimed to examine the effect of the long-term 30 moderate weight reduction on gene expression in adipose tissue (AT) and to identify genes and gene clusters responsive to treatment and thereby likely contributing to the development of the metabolic syndrome. Thus, randomized controlled and individualized weight reduction and physical exercise intervention was conducted. In the WR group, glucose metabolism improved that was not seen in other groups. Moreover, an inverse correlation between the change in SI and the change in body weight was found (r =-0.44, p=0.026). Down-regulation of gene expression (p<0.01) involving gene ontology groups of extracellular matrix, cell death was seen. Such changes did not occur in the other groups.


Condition Intervention
Insulin Resistance
Metabolic Syndrome
Behavioral: Weight reduction, Resistance training, Aerobic exercise training, Control

MedlinePlus related topics: Exercise and Physical Fitness Obesity Weight Control
Drug Information available for: Insulin Lipids
U.S. FDA Resources
Study Type: Interventional
Study Design: Basic Science, Randomized, Open Label, Active Control, Parallel Assignment
Official Title: Gene Expression in Adipose Tissue of Genes Involved in Obesity, Insulin Resistance and Lipid Metabolism Before and After Weight Loss or an Intensive Exercise Period

Further study details as provided by University of Kuopio:

Enrollment: 75
Study Start Date: October 2003
Study Completion Date: December 2005
Primary Completion Date: December 2004 (Final data collection date for primary outcome measure)
Intervention Details:
    Behavioral: Weight reduction, Resistance training, Aerobic exercise training, Control
    Weight reduction: 12 weeks intensive weight loss, 20 weeks maintenance Resistance and aerobic exercise training: individualized and progressive training programs
Detailed Description:

The objective of the study is to examine the expression of genes and gene regions involved in obesity, insulin resistance and lipid metabolism. We aim to identify new genes which are involved in the development of metabolic aberrations characteristic of metabolic syndrome/type 2 diabetes. Obesity and type 2 diabetes are increasing medical and public health problems globally. Low HDL cholesterol and elevated triglyceride concentrations, and altered cholesterol metabolism are common in these states. More knowledge is urgently needed of the role of genetics in obesity, insulin resistance and abnormal lipid metabolism and their mutual relationship. This would enable the early detection of subjects at increased risk of developing obesity and the common abnormalities related to it, i.e. insulin resistance and abnormal lipid metabolism, as well as identification of subjects with genotypes associated with increased risk for above mentioned metabolic states and atherosclerotic vascular diseases and decreased responsiveness to conventional treatment. Because both weight loss and regular physical exercise result in substantial changes in glucose, insulin and lipid metabolism, studies aiming to explore the function of relevant genes are highly interesting. In this study, gene expression will be measured in adipose tissue and leucocytes before and after weight loss or period of regular physical exercise.

Originally, the Genobin study included 75 middle-aged (mean age 60±7 years) overweight or obese (mean BMI 32.9±2.8 kg/m2) men and women with impaired fasting glucose (fasting plasma glucose concentration 5.6-7.0 mmol/l) or impaired glucose tolerance (2-hour plasma glucose concentration 7.8-11.0 mmol/l and fasting plasma glucose <7.1 mmol/l) and two additional features of metabolic syndrome according to the Adult Treatment Panel III criteria [49] (for details see [50]). Subjects were randomized to one of the following groups: weight reduction (WR) (n=28), aerobic exercise training (n=15), resistance exercise training (n=14) or control group (n=18). Subjects were matched for age, sex and the status of glucose metabolism. In addition, 11 normal-weight subjects (mean age 48±9 years, mean BMI 23.7±1.9 kg/m2) were recruited. The intervention was performed in accordance with the standards of the Helsinki Declaration. The Ethics Committee of the District Hospital Region of Northern Savo and Kuopio University Hospital approved the study plan, and all participants gave written informed consent.

At the beginning of the study and after 9-11 months the following measurements were performed: plasma/serum concentrations of glucose, insulin, total and lipoprotein lipids, free fatty acids, non-cholesterol sterols, glycerol, leptin, adiponectin, ghrelin, tumor necrosis factor α, and C-reactive protein, waist and hip circumferences, body composition and resting energy expenditure. A DNA sample were drawn and an adipose tissue biopsy was performed. A frequently sampled intravenous glucose tolerance test (FSIGT) was performed to assess insulin sensitivity and secretion. Given biochemical measurements were performed also at 3 months.

  Eligibility

Ages Eligible for Study:   40 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • The subjects had impaired fasting glycemia (fasting plasma glucose concentration 5.6-7.0 mmol/L) or impaired glucose tolerance (2-hour plasma glucose concentration 7.8-11.0 mmol/L)
  • AND at least 2 other features of the metabolic syndrome according to the Adult Treatment Panel III criteria as modified by the AHA:
  • waist circumference >102 cm (males)/ >88 cm (females)
  • fasting serum triacylglycerol concentration >1.7 mmol/L
  • fasting serum HDL-cholesterol <1.0 mmol/L (males) / <1.3 mmol/L (females)
  • blood pressure >130/80 mmHg.

Exclusion Criteria:

  • liver, kidney and thyroid dysfunction
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00621205

Locations
Finland
University of Kuopio, School of Public Health and Clinical Nutrition, Department of Clinical Nutrition and Food and Health Research Centre
Kuopio, Finland, FI-70211
Sponsors and Collaborators
University of Kuopio
Wageningen University
Investigators
Principal Investigator: Helena Gylling, Professor Unievrsity of Kuopio
Study Director: Matti IJ Uusitupa, Professor University of Kuopio
  More Information

Publications of Results:
Publications indexed to this study:
Responsible Party: University of Kuopio ( Helena Gylling /Professor )
Study ID Numbers: 152/2002, Finnish Academy 210449
Study First Received: February 11, 2008
Last Updated: February 11, 2008
ClinicalTrials.gov Identifier: NCT00621205  
Health Authority: Finland: Ethics Committee

Keywords provided by University of Kuopio:
Insulin resistance, weight reduction, adipose tissue, peripheral
mononuclear cells, gene expression profile, transcriptomics

Study placed in the following topic categories:
Body Weight
Hyperinsulinism
Obesity
Metabolic Diseases
Weight Loss
Insulin Resistance
Metabolic disorder
Glucose Metabolism Disorders
Insulin

Additional relevant MeSH terms:
Pathologic Processes
Disease
Syndrome

ClinicalTrials.gov processed this record on January 16, 2009